305: Prospective Clinical Evaluation of New Ecco2r Technology With Ulpv in Moderate Ards Patients

Introduction: This multicenter, prospective, study in France evaluated the safety and effectiveness of PRISMALUNG+ (PL+), a new ECCO2R membrane lung designed for use alone or with continuous renal replacement therapy (CRRT safety was monitored until discharge or day 28. Results: Data are presented as median IQR, unless stated otherwise. Among 58 (PL+=42 patients; CRRT p = 0.2704) while baseline PaCO2 was 42.0 39.0-46.0 mmHg compared to 45.2 41.0-50.1 mmHg at 24 hours (p=0.0025). CO2 clearance after 8h was 82.3 mL/min (PL+) and 77.3 mL/min (CRRT however, 2 patients experienced minor ischemic strokes post-treatment, unrelated to the device. Conclusions: PL+ effectively and safely clears CO2 and enables ULPV without causing hypercapnic acidosis.